Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist
| Autor: | Nidal Al-Huniti, Hongmei Xu, Eike Floettmann, Khanh Bui, Diansong Zhou |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Narcotic Antagonists Receptors Opioid mu Pharmacology 030226 pharmacology & pharmacy Polyethylene Glycols 03 medical and health sciences Naloxegol chemistry.chemical_compound 0302 clinical medicine Pharmacokinetics Internal medicine medicine Humans Pharmacology (medical) Chemistry Antagonist Receptor antagonist Bioavailability Endocrinology Morphinans Opioid 030220 oncology & carcinogenesis Morphine Drug metabolism medicine.drug |
| Zdroj: | Clinical Pharmacokinetics. 56:573-582 |
| ISSN: | 1179-1926 0312-5963 |
| DOI: | 10.1007/s40262-016-0479-z |
| Popis: | Naloxegol is a peripherally acting µ-opioid receptor antagonist approved for use as an orally administered tablet (therapeutic doses of 12.5 and 25 mg) for the treatment of opioid-induced constipation. Over a wide dose range (i.e. single supratherapeutic doses up to 1000 mg in healthy volunteers), the pharmacokinetic properties of naloxegol appear to be time- and dose-independent. Naloxegol is rapidly absorbed, with mean time to maximum plasma concentration of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink